Eli Lilly secures patent win against Dr Reddy’s

A US court handed victory to Eli Lilly late last week after finding that a drug for which Dr Reddy’s is seeking approval would infringe a patent covering cancer treatment Alimta (pemetrexed for injection).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Fed Circ affirms Eli Lilly victories over cancer drugs

13 August 2019 The US Court of Appeals for the Federal Circuit last week affirmed two findings that Dr Reddy’s and Hospira had infringed Eli Lilly’s cancer drug Alimta.

Americas

Eli Lilly collaborates with AC Immune to develop Alzheimer’s treatment

12 December 2018 Global pharmaceutical company Eli Lilly has entered into a licence and collaboration agreement with Swiss biotechnology company AC Immune.

Americas

Eli Lilly wins Alimta dispute against Sun

3 May 2017 A judge at the US District Court for the Southern District of Indiana has handed down a final judgment in a patent dispute between Eli Lilly and Sun Pharmaceutical favouring Eli Lilly.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Eli Lilly secures patent win against Dr Reddy’s

More on this story

Editor's picks

Editor's picks

More features